2025/01/05 by Cristina Pascual‐Izquierdo, Cristina Pascual, Ma. Jose Llacer‐Ferrandis +21 · 3 citations
Medicine · #Platelet Disorders and Treatments #Blood groups and transfusion #Autoimmune Bullous Skin Diseases
paper · pdf · doi:10.1111/bjh.19975
Immune thrombocytopenia (ITP) is a rare acquired disorder where thrombopoietin-receptor agonists have become mainstays of ITP treatment. With the recent approval of avatrombopag (AVA), real-world studies are essential to evaluate its efficacy and safety. Our study of 66 adult ITP patients treated with AVA showed a high response rate. After starting AVA, 74.2% did not require rescue medications, with minimal adverse effects. Additionally, 56.0% of patients reduced other ITP medications, and all patients aged ≥65 years responded to AVA. Results should be confirmed in larger studies, but AVA appears to be an effective and safe treatment for ITP patients.